MX2022007654A - Compuestos inhibidores de la oga. - Google Patents

Compuestos inhibidores de la oga.

Info

Publication number
MX2022007654A
MX2022007654A MX2022007654A MX2022007654A MX2022007654A MX 2022007654 A MX2022007654 A MX 2022007654A MX 2022007654 A MX2022007654 A MX 2022007654A MX 2022007654 A MX2022007654 A MX 2022007654A MX 2022007654 A MX2022007654 A MX 2022007654A
Authority
MX
Mexico
Prior art keywords
compounds
oga
compositions
inhibitor compounds
oga inhibitor
Prior art date
Application number
MX2022007654A
Other languages
English (en)
Inventor
José Manuel Bartolomé-Nebreda
Lucas Olivares Ana Isabel De
Petrus Jacobus Johannes Antonius Buijnsters
Daniel Oehlrich
Adriana Ingrid Velter
Andrés Avelino Trabanco-Suárez
Lamenca Carolina Martinez
Joseph Elisabeth Leenaerts
Van Roosbroeck Yves Emiel M
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2022007654A publication Critical patent/MX2022007654A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a inhibidores de la O-GlcNAc hidrolasa (OGA). La invención también se refiere a composiciones farmacéuticas que comprenden dichos compuestos, a procesos para preparar dichos compuestos y composiciones, y al uso de dichos compuestos y composiciones para la prevención y el tratamiento de trastornos en los que la inhibición de la OGA es beneficiosa, tales como tauopatías, en particular, la enfermedad de Alzheimer o la parálisis supranuclear progresiva; y enfermedades neurodegenerativas acompañadas de una patología tau, en particular, la esclerosis lateral amiotrófica o la demencia del lóbulo frontotemporal provocada por mutaciones C9ORF72.
MX2022007654A 2019-12-18 2020-12-18 Compuestos inhibidores de la oga. MX2022007654A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19383138 2019-12-18
EP20197523 2020-09-22
EP20203022 2020-10-21
PCT/EP2020/087201 WO2021123294A1 (en) 2019-12-18 2020-12-18 Oga inhibitor compounds

Publications (1)

Publication Number Publication Date
MX2022007654A true MX2022007654A (es) 2022-07-19

Family

ID=74130209

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007654A MX2022007654A (es) 2019-12-18 2020-12-18 Compuestos inhibidores de la oga.

Country Status (11)

Country Link
US (1) US20230099293A1 (es)
EP (1) EP4077323A1 (es)
JP (1) JP2023507184A (es)
KR (1) KR20220118483A (es)
CN (1) CN114867725A (es)
AU (1) AU2020409728A1 (es)
BR (1) BR112022011810A2 (es)
CA (1) CA3160405A1 (es)
IL (1) IL293931A (es)
MX (1) MX2022007654A (es)
WO (1) WO2021123294A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202346267A (zh) 2022-03-07 2023-12-01 美商安進公司 用於製備４－甲基－２－丙－２－基－吡啶－３－甲腈之方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2174746A1 (en) * 1972-03-09 1973-10-19 Anvar 1-methyl-4-anlino-5-aza indoles - antiinflammatories
GB201103526D0 (en) 2011-03-02 2011-04-13 Summit Corp Plc Selective glycosidase inhibitors and uses thereof
ES2723883T3 (es) 2013-03-14 2019-09-03 Merck Patent Gmbh Inhibidores de glicosidasa
EP2818472A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators
EP3186243B1 (en) 2014-08-28 2021-07-21 Asceneuron SA Glycosidase inhibitors
WO2017106254A1 (en) 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
DE102015122932A1 (de) 2015-12-29 2017-06-29 fos4X GmbH Verfahren zum Prognostizieren der Anlagerung von Eis an einem Rotorblatt einer Windkraftanlage und dessen Verwendung
WO2017144637A1 (en) 2016-02-25 2017-08-31 Asceneuron S. A. Acid addition salts of piperazine derivatives
US11612599B2 (en) 2016-02-25 2023-03-28 Asceneuron Sa Glycosidase inhibitors
CN110312716A (zh) * 2016-12-16 2019-10-08 詹森药业有限公司 双环oga抑制剂化合物
TWI654978B (zh) 2017-01-27 2019-04-01 美商美國禮來大藥廠 5－甲基－1,2,4－二唑－3－基化合物
TWI669302B (zh) 2017-05-25 2019-08-21 美商美國禮來大藥廠 5-甲基-1,3,4-<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>二唑-2-基化合物
CA3093315A1 (en) 2018-03-14 2019-09-19 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors

Also Published As

Publication number Publication date
BR112022011810A2 (pt) 2022-08-30
EP4077323A1 (en) 2022-10-26
CA3160405A1 (en) 2021-06-24
KR20220118483A (ko) 2022-08-25
CN114867725A (zh) 2022-08-05
WO2021123294A1 (en) 2021-06-24
JP2023507184A (ja) 2023-02-21
US20230099293A1 (en) 2023-03-30
AU2020409728A1 (en) 2022-08-11
IL293931A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
MA53937B1 (fr) Compositions comprenant des souches bactériennes
MX2021004431A (es) Procesos novedosos.
PH12017500841B1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
JO3459B1 (ar) تركيبات صيدلانية لعلاج مرض الزهايمر
MA39219B1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
TN2017000134A1 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer&#39;s disease
MX357383B (es) Derivados de 5-(3-aminofenil)-5-alquil-5,6-dihidro-2h-[1,4]oxazin- 3-amina.
MX2016010777A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer.
MX2012007273A (es) Pteridinonas como inhibidores de la quinasa tipo polo.
EA200971050A1 (ru) Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
MY187450A (en) Heteroaryl amides as inhibitors of protein aggregation
EA201291413A1 (ru) Производные 3-амино-5,6-дигидро-1h-пиразин-2-она, применимые для лечения болезни альцгеймера и других форм деменции
MX357384B (es) Derivados de 6-difluorometil-5,6-dihidro-2h-[1,4]oxazin-3-amina.
WO2019075456A3 (en) Methods and substances for prevention and treatment of neurodegenerative diseases
MXPA05012196A (es) Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos.
MX2022007654A (es) Compuestos inhibidores de la oga.
CR20210163A (es) Inhibidores de pde4 que contienen boro
WO2019016247A3 (en) Agents, uses and methods for treatment
MX2023007476A (es) Derivado de tetrahidroquinolina y uso medico del mismo.
MX2019014306A (es) Agente para reducir la cantidad de proteina beta amiloide.
WO2020117031A3 (en) Composition and method for inhibiting amyloid beta accumulation and/or aggregation
BR112022011812A2 (pt) Compostos inibidores da oga
MX2018003565A (es) Derivados de 2,3,4,5-tetrahidropiridin-6-amina.
MX2019008603A (es) Una composicion farmaceutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevencion de la enfermedad de alzheimer.
MA54630B1 (fr) N,n-bis-2-mercaptoéthyle isophtalamide pour le traitement des maladies neurodégénératives